#Daily comics online a z trial#

Load factor improved to 80.7% from 44.9% but came up shy of expectations of 82.1%. Total revenue rose 161.0% to $4.68 billion, above the FactSet consensus of $4.58 billion, as passenger revenue grew 190.7% to $4.23 billion. Excluding non-recurring items, such as $763 million in benefits related to the Payroll Support Program, adjusted per-share losses came to 23 cents, compared with the FactSet loss consensus of 27 cents. The company swung to net income of $446 million, or 73 cents a share, from a loss of $1.16 billion, or $1.96 a share, in the year-ago period. The air carrier's stock was little changed in premarket trading. reported Thursday a narrower-than-expected third-quarter loss as passenger revenue nearly tripled, as overall demand remained 'quite strong' despite a deceleration in traffic in August and September as a result of surging COVID-19 cases. Southwest results beat expectations, sees 'operational challenges' in October costing $75 million in revenue The SPDR S&P Biotech ETF undefined has fallen 12% and the S&P 500 undefined has gained 21%.

Pfizer shares have gained 16% in the year to date, while BioNTech has gained 230.5%. Pfizer shares jumped about 1% premarket, while BioNTech was up 1.8%. The companies are planning to submit the data to the Food and Drug Administration, the European Medicines Agency and other regulators around the world. 'These important data add to the body of evidence suggesting that a booster dose of our vaccine can help protect a broad population of people from this virus and its variants,' said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech, in a joint statement with Pfizer CEO Albert Bourla.

#Daily comics online a z trial#

The companies said the Phase 3 trial involved more than 10,000 people aged 16 and older, who had already received the primary two-dose series, and found the booster restored vaccine protection against COVID to the high levels achieved after the second dose. undefined and German partner BioNTech SE undefined said Thursday a late-stage trial of a 30 mg booster dose of their COVID-19 vaccine showed efficacy of 95.6% compared with those who received a placebo. Pfizer and BioNTech say Phase 3 trial found booster dose of COVID vaccine had 95.6% efficacy against disease